Press ReleasesGo to press page
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based Coronary Artery Disease (CAD) rule-out.
The CE-mark approved and FDA De Novo cleared Acarix CADScor®System is for patients experiencing chest pain with suspected CAD and is designed to help reduce millions of unnecessary, invasive, costly diagnostic procedures. CADScor®System calculates a patient-specific CAD-score non-invasively in less than 10 minutes with 96% confidence.¹
Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX).
Go to contact page
Please visit our contact page to get in touch.
- US user manual v.12.5, prevalence 10,7%, algorithm version US3.2